The Alaska legislature has approved a bill to create a task force dedicated to preparing the state for the potential federal legalization of psychedelic therapies. Introduced by Representative Jennie Armstrong, an Anchorage Democrat, the bill passed on May 10. The task force will not advocate for or against the use of psychedelic treatments but will focus on ensuring that Alaska is ready if the U.S. Food and Drug Administration (FDA) approves such therapies.
The FDA is anticipated to make a decision this fall regarding the approval of MDMA, commonly known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD). This decision is particularly significant for Alaska, where PTSD rates are higher among veterans, first responders, and Alaska Native people compared to the general population, as reported by Alaska Public Media.
Representative Armstrong highlighted that the task force’s primary goal will be to guarantee that any federally approved psychedelic therapies are covered by insurance, including Medicaid. This would ensure that all Alaskans have access to these treatments. The task force is expected to include advocates for the healthcare needs of Alaska Native people, veterans, and survivors of domestic violence and sexual assault.
“When you look at the rates of trauma, harm, mental health issues, addiction issues, and suicide rates in our state… you can just imagine how profound that is going to be on the state of Alaska if we can ensure that those who qualify and need this medicine can get access to it,” Armstrong said.
Unlike some states that have moved to decriminalize psychedelics, Alaska’s approach is to align with potential FDA approvals rather than pursue state-level legalization. The task force will focus on developing recommendations for licensing, insurance coverage, and regulations for psychedelic treatments.
Under the measure’s guidelines, the task force will operate for one year. The bill now awaits the signature of Governor Mike Dunleavy, a Republican. If signed into law, this task force will play a crucial role in shaping the future of psychedelic therapies in Alaska, ensuring that these treatments are accessible and regulated appropriately.